Title of each class Trading symbol(s) Name of each exchange on which registered Common Stock, Par Value $0.0001 per share CRVS Nasdaq Global Market Table of Contents- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition ...

EXHIBIT 99.1 Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Enrolling Patients in Second Dosing Cohort Interim Data from Atopic Dermatitis Trial Expected to be Announced December 2024 Registration Phase 3 Clinical Trial of Soquelitinib in Peripheral T Cell Lymphoma (PTCL) Enrolling with Multiple Clinical Sites Open Conference call today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif., Nov. 12, 2024 (GLO ...

Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Enrolling Patients in Second Dosing Cohort Interim Data from Atopic Dermatitis Trial Expected to be Announced December 2024 Registration Phase 3 Clinical Trial of Soquelitinib in Peripheral T Cell Lymphoma (PTCL) Enrolling with Multiple Clinical Sites Open Conference call today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharm ...

BURLINGAME, Calif., Nov. 09, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new data highlighting the potential of ciforadenant, the Company’s adenosine A2A receptor antagonist, to overcome resistance to anti-PD1 immunotherapy in the treatment of metastatic castration resistant prostate cancer (mCRPC). The data were presented today in an oral session at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting by Ara ...

BURLINGAME, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on November 12, 2024 at 4:30 pm ET (1:30 pm PT) to provide a business update and report third quarter 2024 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone acc ...

Shares of Corvus Pharmaceuticals (CRVS) gained 13.9% on Sept. 10 after the company announced the initiation of a phase III registrational study of its lead product candidate, soquelitinib, to treat patients with relapsed/refractory peripheral T-cell lymphoma (PTCL). Corvus' soquelitinib is an investigational, oral, small-molecule drug that selectively inhibits interleukin-2 inducible T-cell kinase (ITK), a protein tyrosine kinase that plays a role in T-cell development and differentiation. The company belie ...

Soquelitinib is a potential first-in-class ITK inhibitor with broad potential in cancer and immune diseases There are currently no fully approved agents for the treatment of relapsed PTCL and soquelitinib has been granted Orphan Drug Designation and Fast Track Designation by the FDA BURLINGAME, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it has initiated a registrational Phase 3 clinical trial of soq ...

Corvus Corporate Presentation August 2024 Focus on ITK Inhibitors with Broad Opportunities in Cancer & Immune Diseases Forward-Looking Statements / Safe Harbor 2 This presentation and the accompanying oral presentation contain "forward‐looking" statements, including statements related to the potential safety and efficacy of soquelitinib, ciforadenant and mupadolimab; the Company's ability and Angel Pharmaceutical's ability to develop and advance product candidates into and successfully complete preclinical ...

Financial Data and Key Metrics Changes - Research and development expenses for Q2 2024 totaled $4.1 million, slightly up from $4.0 million in Q2 2023 [3] - The net loss for Q2 2024 was $4.3 million, a decrease from a net loss of $6.5 million in Q2 2023 [4] - Cash, cash equivalents, and marketable securities as of June 30, 2024, amounted to $47.3 million, compared to $27.1 million at the end of 2023 [5] Business Line Data and Key Metrics Changes - The company is advancing its lead ITK inhibitor, soquelitinib, which is showing potential in treating a range of immune diseases and cancers [6][7] - The Phase 1 clinical trial for soquelitinib in patients with moderate to severe atopic dermatitis is currently enrolling patients, with early signs of clinical activity observed [9][10] - In the Phase 3 eligible patients for peripheral T-cell lymphoma (PTCL), the objective response rate (ORR) remains at 39%, with a complete response rate of 26% [12][13] Market Data and Key Metrics Changes - The company is preparing to begin enrollment in a registrational Phase 3 clinical trial for soquelitinib in relapsed PTCL in September 2024 [14] - The FDA has granted Orphan Drug designation and Fast Track designation for soquelitinib for the treatment of relapsed T-cell lymphoma [14] Company Strategy and Development Direction - The company is focusing on the development of selective ITK inhibition as a new therapeutic modality for various immune diseases and cancers [6][7] - There is a strong emphasis on advancing soquelitinib in both immune diseases and cancer, with ongoing discussions for potential partnerships to enhance program efficiency [34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of soquelitinib and its unique mechanism of action, which may address a wide range of immune and inflammatory diseases [10][19] - The company anticipates important clinical milestones for soquelitinib in the remainder of 2024, including interim results from the atopic dermatitis trial and the initiation of the Phase 3 trial for PTCL [19][20] Other Important Information - The company has raised $30.3 million in financing in May 2024, which is expected to provide a cash runway into the fourth quarter of 2025 [5] - The company is also advancing second- and third-generation ITK inhibitors, with potential clinical studies expected in 12 to 15 months [38] Q&A Session Summary Question: Expectations for Phase 1 data from atopic dermatitis - Management expects to report safety and efficacy data on the first two cohorts of the clinical trial by Q4, aiming for a majority of patients to show over 50% improvement in EASI scores [22][23] Question: Patient baseline for Phase 1 atopic dermatitis study - Management indicated that the patient mix could include those with prior biologics and those with multiple prior lines of therapy, making it difficult to predict the exact baseline [28] Question: Rationale for selecting renal cell cancer as the first solid tumor - The choice was based on renal cell cancer being an immune-responsive disease, with prior mouse data showing effectiveness against tumors resistant to anti-PD-1 therapy [30][32] Question: Strategic decisions regarding partnerships for expanding programs - Management is actively pursuing partnerships while pushing forward with both immune diseases and cancer programs as quickly as possible [34] Question: Timeline for the pivotal Phase 3 study - The Phase 3 trial is set to start in September, with an interim analysis expected about a year after enrollment begins [47]

Title of each class Trading symbol(s) Name of each exchange on which registered Common Stock, Par Value $0.0001 per share CRVS Nasdaq Global Market Table of Contents- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition peri ...